177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas By Ogkologos - September 2, 2025 257 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Phase II study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer Potential Role of an Activated Tumour Immune Microenvironment in Predicting Benefit from Atezolizumab for TNBC Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC MOST POPULAR New Approach May Help People with Cancer Better Manage Depression, Pain,... May 14, 2024 Drug Combination Shows Promise for Rhabdomyosarcoma, but Can It Get to... December 9, 2022 Reunión anual de la American Society of Clinical Oncology de 2023:... June 4, 2023 Altering Chemotherapy Improves Outcomes in Early-Stage Pancreatic Cancer June 28, 2018 Load more HOT NEWS Osimertinib Shows Promising Activity in Previously Untreated Patients with Metastatic NSCLC... When You Lose a Spouse to Cancer and Need Support Self-care Isn’t Selfish New option to treat advanced oesophageal cancer approved for NHS in...
